<SEC-DOCUMENT>0001193125-13-214366.txt : 20130510
<SEC-HEADER>0001193125-13-214366.hdr.sgml : 20130510
<ACCEPTANCE-DATETIME>20130510163837
ACCESSION NUMBER:		0001193125-13-214366
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130510
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130510
DATE AS OF CHANGE:		20130510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		13834059

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d536888d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>May&nbsp;10, 2013 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>GALECTIN
THERAPEUTICS INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEVADA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-31791</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4960 Peachtree Industrial Blvd., Suite 240 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Norcross, GA 30071 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(678) 620-3186
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations and Financial Condition </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;10, 2013, Galectin Therapeutics&nbsp;Inc. issued a press release (the &#147;Release&#148;) containing financial information regarding its results of operations and financial condition for the
three months ended March&nbsp;31, 2013.&nbsp;Exhibit&nbsp;99.1 hereto, which is being furnished and not filed herewith, contains the text of the Release. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release issued May&nbsp;10, 2013</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GALECTIN THERAPEUTICS INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Thomas A. McGauley</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thomas A. McGauley</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief
Financial Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;10, 2013 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d536888dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g536888logo001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Galectin Therapeutics Reports First Quarter 2013 Financial Results </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Norcross, GA (May 10, 2013) &#150; Galectin Therapeutics Inc. (NASDAQ: GALT)</B>, the leading developer of therapeutics that target galectin proteins
to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March&nbsp;31, 2013. These results are included in the Company&#146;s Quarterly Report on Form 10-Q, which has been filed with the SEC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;During the first quarter of 2013 we completed a significant milestone with the submission of an IND for GR-MD-02 and the FDA&#146;s ok that we
could proceed with a Phase 1 clinical trial,&#148; said Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. &#147;We engaged CTI Clinical Trial Services to provide services related to a Phase 1
clinical trial of GR-MD-02 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and expect to begin enrolling patients in this trial in the second quarter of 2013, with expected top line results sometime late in 2013 or early
2014. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic
options.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">At March&nbsp;31, 2013, the Company had $7.0 million of non-restricted cash and cash equivalents available to fund future
operations and the Company believes is sufficient cash to fund core operations and planned research and development through the first quarter of 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the first quarter of 2013, the Company reported a net loss applicable to common stock of $3.5 million, or ($0.22) per share, basic and diluted, compared with a net loss of $2.2 million or ($0.17) per
share for the same period in 2012. The weighted average number of shares used to calculate loss per share increased for the 2013 period compared to the 2012 period due primarily to the March 2012 offering of 2.7&nbsp;million common shares as well as
the payment of dividends in common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense for the first quarter of 2013 was $1.8 million, compared with $0.9
million for the same period in 2012. The increase is due primarily to clinical program expenses related to the Phase I clinical trial agreement we entered into with CTI during the three months ended March&nbsp;31, 2013. As we begin enrolling
patients in the Phase I trial we expect our clinical activities costs may increase and will fluctuate from quarter to quarter as the trial progresses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense for the first quarter of 2013 was $1.5 million, compared with $1.1 million for the same period in 2012. The primary reasons for the increase is due to increased
stock-based compensation, legal expenses and public company related costs, offset by decreased facilities costs as we moved the location of our headquarters to Georgia. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Galectin Therapeutics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company&#146;s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development
expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver
fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g536888logo001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future
events or future financial performance, and use words such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on our current expectations and are subject to factors and uncertainties which
could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of
operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance,
inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge
which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B>Tom McGauley, Chief Financial Officer, 678-620-3186, <U>ir@galectintherapeutics.com</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics and its associated logo is a trademark of Galectin Therapeutics Inc. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Condensed Consolidated Statements of Operations </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>(in thousands, except<BR>per share data)<B></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>(unaudited)<B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">901</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,052</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock dividends and accretion costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss applicable to common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,472</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares used in computing basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g536888logo001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Condensed Consolidated Balance Sheet Data </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>(in thousands, unaudited)<B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,561</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,473</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,644</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,036</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g536888logo001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g536888logo001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.`#S`P$1``(1`0,1`?_$`+P```$$`@,!````````
M``````D`!P@*!`8#!0L"`0$``04!`0$`````````````!0(#!`8'"0$($```
M!P`!`P(#`P8$$0T````!`@,$!08'"``1"1(3(10*T5*2,5$B,A460;87>(&Q
M0K(C)%9V-W>7M]<XN#D:87%B<C/35)0FEM88&1$``@("`0,"!`,##`,!````
M`0(``Q$$!2$2!C$342(R!T%Q%&&S"8&1L<%R=!4U=38W"%(C,Q;_V@`,`P$`
M`A$#$0`_`+QW(+?,IXOX[HV_;C<H^AY1E=;=VFY6:2.;VF,>T*0B35HV3]3B
M1F99ZLDT8LT2G</'BZ2*13*'*`HE7KBGS`\I'GSO-TT+COI<OXS/%_2K5)4Z
M*TFIU>M6GEAOTI%^KY]A6K-:VDY7:4=JFX1,^?1C<&L.L<&I%)5<BPH(AB8K
MQ-4:(CD2-^='E?<6=$@F+=Y/R-<B)B1,]'XFD%:7+6)[D*Q_<_2!L>MF8!^J
M"'H_1Z1(-\NN;O-SPOT2X7#E#897G#P_FJM:H7).4,51:W6>0V%[2>MR1\NH
MW)NI5)K!YSH6>7FS(-HYG<(IA$KMWRGMR#,XJHF41"[>/+8-!W_@CQ`W'599
MM-:5K?'7)]#ODNPC64(RDK7:Z?%S$V\:1$6DWCHQNN_=',1!`A$DRB`%``#I
M$F-ZS_>-^(?MZ1%ZS_>-^(?MZ1/DQE#%,4%#D,8IBE.`]Q(82B`'`#=RB)!'
MOV'X#VZ1*+_DUY!>5;A+Y<_'+QHG/))J>N<?.2^LXI8EHB.SG+,5E/V4IND7
M4K=GUH=Y96X9>R0;J/\`:`QA71(Z;.S(K(F](G.B7I#&-ZC?I&_6'^$?S](G
MSZS_`'C?B'[>D1>L_P!XWXA^WI$7K/\`>-^(?MZ1%ZS_`'C?B'[>D1>L_P!X
MWXA^WI$7J.(@`&,(C^0.X]Q^'?X?T`Z1%ZS#^0YOS?K#]O2(W,YL>4UB^57+
M;+J%`KVF7I!VZI.>3=S@(N[VYJQ]?SCFM59Z_1FII%O[1_49NBH'<A@_J1[8
MS[FI5>NK98B[+_2I8!F_(9R9)Z_"\QM\?=RVKJ[%G%ZY`MN6MVJK)]`]@!53
M^9'J(XWK/]XWXA^WK)D9%ZS_`'C?B'[>D1>L_P!XWXA^WI$7K/\`>-^(?MZ1
M`C^<+R"<@?'OBV*7[CZE1W-@T#59"ES:-[K;ZSLC1;>IR,RW".:L9J%50?&?
M-2AZO6<#%'MZ>_QZ@.<WMK3-(UG"!RV<@'T`QC/YS];_`/47[*^%_>SRKEN'
M\V.VNEI<<M]9U[5J;O-RH>XLE@*]I/3`Z]<S)\?]I\Q?(6L5[6>6-FPGCMG]
M@;MI6"SN%Q>3D-FGXAP!%6SV90FKRI"YZV?H&`Z*;I%Y(>D>ZC9'X>JQI+S^
MT!;;<M5!]/\`UJ6/[<>@'Y_G*/O3H_\`5WPCD;_&OMQK\QSG-4,4LV7WE71K
M<>JH4UP^R5/0E&2O/TV/UP:E,QFY$$'#SW%Q(4ON+G106<G*`%,J"!/;(!E#
M!W$"%`H"/8`[=;*`0`"<GXS\FL0S$J`JD^G4X_9UZ]/VQ@MJA^2PQSN5P6^4
M9M+H)&51I^A5`74?(B0@F^69V>.DV2\<X6,``07*"R8F'](Y0^(?93`J6_R5
M\UJ#99>GW2#H-;LT"[.RE8>3H[U%TU6)V$I@_P#4(IKMUTQ`Z2J9C)*IF`Q#
M"`@/2)K?_P"K?*[\^8_^S7G_`,@Z1)2\2^<O*;D/>K?1`5R1*<;9I9+#45)B
MM3[&NDM$:[B48\UE4A)I:95@P3>*>\1KZ5A'TB4?@("B1!UKS@\E<$Q/-]&O
MF#XU<K3N'$RR;EDT%GDYHS>+4U@9MS*4_,+0O,MW;EM7DL=SO0+)+S!10(D:
MN(MDB=W('Z1+//2)YS7UE?D,O<]N5#\;M/EOD,LHE3HFWZVU9J'1=6+3)_\`
M>K]TX.7.DJ`.H6O4]TRDDVRI1(+QXFK\3))B5$NS^,+`(#B]X\^&^'UY@E'H
M4SCYFJLR1)$B(N[C9ZXSMMYE%RD`/4ZE;?./7"AA[F,93XCTB3NZ1(S\S>.E
M<Y<<4.0_&BU1[*2B=JR.[45))^)2MV<]*PKG]U)HJABG^6=U^T)LWS=<`]2"
M[<JA?B4.D36?'[C%YXZ<'.)&":<C%M]%QSCWE>;W="$D22\0E9ZC48R&F21D
MHFDB209`]:']M4"%`Y>P]@_)TB;9R4YA<8.'E:AK;R;V^AXY$6:5+!51&U29
MQL-QFC&3+^R*54(M"1MEQE"F6(`MXQDZ5**A>Y0]0=T2(Z'FF\:2-IK=/MO(
MU?))BY/TXRI.-[QO>,`K=C?JJE2(VBKCLV94>I.%!,<OY7H?`Y1_((#TB%#;
M.FSUN@[9N$';1T@BY:NFRJ;ALZ;.$RK-W+9PB8Z2[==(X&(<HB4Q1`0'L/2)
M2#^HY_WWO@I_O_H'^TQ2ND2\*?\`6-_UC?TQZ1(.;OY(N%'&_00R'4=RC!V$
ML4G.N<?SBIW[:]7BX14Q`1EY_.L:JM\MU;C%RJ`9->0:-DE"CW(80Z1-DXP<
M]^'W,QQ:XSC7N]1T>ST,X)WJ@BC.5#3J2;WBMC&MN87F)K5_KR!'9@1%5U')
M)>]^AZO5\.D27OQ_@`1'\P?$>D0<.G>7#QX9/H-BR><Y'1=OTJG*D0N=*Q.A
MZER$G*6X/Z@^5N2&&4C0DJF](8@E,A(';K%-\!(`](C_`'&7FIQ1YE0LW.<8
M=WH&PHU9^>+ML37)-5K;Z9)$5,@9A=:).-XJZ4]Y[Y#$!.28-3B<AB@`B40!
M$KK>?+SP\8<6R^;X4<?-K86KD_HFG5#,]/EJ%+OFS'CG2X:_PBNH/+9=&*C)
MI%7-Q&QCB(2CVSA1TT!PLX<`B5$A5D0^V8^1W@#L]K2HF1\S.-6C7%:*F9Q.
MLT_8*3.3`PM;BW,W89<S-C+JJDC(.&9+.W:YNR;=ND=0YBE*(@B!YY*._!WN
MODQXG<HK?S]HD[REJENS'/LPR?&M>@-&@[_>(^X+FRAK.Q]#B[A(P0-K58/2
ML<'L>Q=$](.#@4#B;7MSQS4W.7JYAW<75]I[1CM8H<KG(R,?B!Z_SSJOCWW>
M\D\;\"W_`+>Z5>JW$[_N=SNA-J"Y0EH4A@I[E&`64E3DC\,'NWCDIQ\XNU%&
M_P#)';<MPFE.Y,L,RM&KW>OT:%D)I1NN\3AHU]8'S%&1EU6C554C5`5%SD3,
M8"B`#UL,Y5&.X_\`DBX*\I:/K^G8/R;S.]9K@4DWB]@T+]I.ZS2**L[BQF&[
MN4M-P90$,K"K,"',600659"9,Y`5]93`")%I+SZ^(`]ZC,]<<WL]B9F;<@UA
M)FPU;4*WGLTI[R3<5HC4YZC1V;R,<"JQ0%XE*&:?I`/N]A#I$+LP?L91DSDX
MMZTDHV1:-I".D8]RB\82#!ZB1RS?,7C<ZC=VS=MU"J)*IF,10A@,41`0'I$C
M9O?%3-^1]^X[V[3V#:P1''709C5*[5)!JF[B9F\+5Q>OUE_+(+`9)PUJZSQ1
M^DB8HE.\20,;N4@E&/V]!-S9HNMP:Z2Q[?B2!C^08R0?6="\,^X_.^"<+SG%
M^/NU.USFDFI9<I(>N@6BRU4(Z@V@"LD>B%P.I!$/_(?S=L6*N&F.9*^28:'*
MQ24M:;6*2;EQ4(61!0L:RB4E@.@6Q2J1#*^\H4P-6_I,4HG4*8LA.>P!DI;;
MO9I5>9F+3<+!-KJ"X<2;V<G).2,H8XF%4S@SI5<GZ9OAV[``_D[=(D\.,7D(
MV/"DGU?N[6SZY2#1CHL)%3CI^:=@)A-(PQWR%A?-W3L8-98`(Y;JBK[9!]:/
M8P>DR)%/=-HTKD/?GNAZ"W]4HLW3CHZ/B8-=E&0D*V56591#,`;BY<I-A7,(
MK.#J+*&,(B(`(`"(SGR;[_P$A_Y!Y_W/2(3+Q1-G!.3<H*S5TD0<MM)?4NU7
M1((FDH`/3ZE4RE$1#O\`#I$L,*TJFKHMVR]1JRS=FR/&M&ZM>AU4&L:HW>M%
M(]LDHS,FW8J-))PD9$@%3%-PH40[*'`43=ND3R*/JIX&=A_.+RUD9A)=./M5
M=XWS]6.L=0R;B!;<:<EJ[A5J4X>E-`+/6Y$@@3]'W2'']83=(GJU<?99C/X)
MAT[%K`XC9K'LQEHYP7]5=C)4F#>-%@_Y%6ZQ3?T>D1QK!)/(:`G)B/A)&S2$
M5#R<DQK<0HP1EK"\8,EW36#BU95VPBTI&672*W0,Y70;E54**BA"=S`B5Q>8
MGU)5!\?\U48'F'XY.>^(O;\RD7]*=3;+CM.05G0AU&B4PG$6.I[G.PCA[$'?
MM_FFWO@X0*ND8Q`*H011)?\`CV\OB_D?3I=PQ_@'S-IN!W1_/Q[7DCI[/$Z]
MEK4]?:R?S3ENV;:W(7FQQYYN,&+!Q%1#U$CX_H.8I4U3)HF`Z\2#FW^9-#RK
MZMOC[2*]0LL:T?CYQTF*:FI&X[8E:F6JS$_&6-U,O&)VAU'DI*MRH1K=X$I*
M&4.N(-R>I$BW]17RAX46GQT<RN+=KOM/T[?&N7.+96LPH\`_UZZ9E;ZC,1LS
M"W2Z$IL9/I8JQBU69B+2\ZXB4B-EE">LY51241'2^F.TBXZ;X6N)4K=YM[8)
M2MGU?/XR1D7"SMZ2JT?5[A`U2+4<.#J*G0@X)LBS;E[]DVZ"9"@!2@'2(&_Z
MCG_?>^"G^_\`S_\`VF*7TB6,/-=SHG?'7XX.1/):DBV#4(Z*B:!D9WC<CQHQ
MTK2)AM5:_/.6BO=%XE4TGKB7]A0!37%B"9OT3#TB!A^GEG^0V*>/JI;'`^/?
M;^0VI\M+5>-RUWE!_+7QIC;!LLI+6^<BX)=ZXT748;02Q4%$1A$DF[]%,HO#
MNG29>SH3&1-%\A7$?RP[IY+^(?D?X/<#)GCOI>)Q+2M;6]N>_<;&3O:JRVM"
M2_[N61"EZ3*H3\*\I+V0B79WOK7,W50*0.[5`Q$1\?JLO)3K?#KBADW''CY8
M9:B[+S1F[)6Y:VP+]5C9ZADU8:0K>X1]=E6ADW$3/7&:M3&,(^0.55)B5Y[1
MB*'34*B'C\>'#G+."/$/%>/64UF)@DJU1*TYO,XR8MT9B_Z3(Q#5[=[W:I(B
M8/)F;L%@<+J^XX.H*"`IH)B5%),A42)%#\..8YGY<M"\L5(V"[5RP:E09&L7
MK`XF'CV-'L=IEZU#5B3MTM/-WY';]D]3@V\F>-59&$9POSGS/P!/I$KQ?6%Q
M44SVKQ(J-(N-:J2&L:JJ_4;1[1!1^H:W8+ZC/5$D2'=B(G,/]D$WQ,8?ZH>Z
M)>$&CTGVG2'[FU3V'S)U'/4?W<A_:>1[]L=H_8.D_DO2X9/FJITEDC@*:J9A
M*8!*(ATB4'/-;QSQ#`OJ*/#Z]Q/*\_R5KI%LXUSENALWJ<+2H.8GX7DN\@D)
MUW"UYI'Q0RZT0@@W57*B515-NF!Q,)0'I$OCZID>5[759*D;!F]&U&GODGI'
M-:O]5A+;#'%TR<L5U2,)QD^;H.3,W*B8*IE*H4IQ`#!WZ1*`OTG?#K+MYU'G
M@;5UI:Y9'@6Q9Q+53CQ,'2=8]8]#3D-.85+1]%K2@"VODOG$1$*I03*2(O&,
MW3Y1[[!G2395%$L__418AFVJ^'?F8-KHU:G7^3Y0?2LW?.HI@5_1K+3)B'?M
MYBKO@1*O#+EBTUVRI6YB`NT640,!B*"4432?IC-#M.D>%?B+(6Z4=3$A6/Y6
M,^C7KU=5RY)6*3K5SA*O'"JL8ZGR\/!MT&B!>_I300(0O8I0`$0^G2)5/\@+
M66:\O=F_;`*@HYEX=VP%43#ZX9>M0XQ9T1'X>P#<OI+V^`"40Z1'5\9^IYAD
M^NWR;U2VUZGPLCG1HN/?6,_H:NI,;'#N@:-Q%!</F/E4#G[=@_1*/_-TB&J_
M^Y_#L?R;?EPC^0`!<!$1'X`'PCQ'N(](DH6Z$6Z;H.D&;!1!RBDX04!D@4%$
M5B%424`#HE,`'3,`]A`!^/2)&S?.7O$OBT_KD7R(V7,<?D+>TD7]79W5TA&K
MSC&)7;-I%TP*5FL"J+-=XD0X]P[&.'6#M\CI:)5=NP(6SC()SCU]`9O_`(9]
MJ_N)]Q*;]CPCB-WDZ-5E6UJ$[A6S@E0W48)"DC\ITF%\ZN%W(^Z+Y_Q_Y!93
MJ%X;PCVQ+URE21'DNE`QR[-L_DSI$9(=F;9P_0(<WJ^!E"_GZHUN6X[<M]C6
MM#6XSC!'I^8$S?+OLU]TO`N*'.>8\'O\=Q+6K4+;D"I[CABJ9R>I"L1^1DON
MI&<SG8=(E.'ZK'PU6KF%FC+GIQRKDK;.0&!4MC5]'SR#:"\E=!PR$>V:P.IB
MNQS9,SR7N-$?V%1S\J0#K.XDJQ4BG622241)[?35^1.A<V_'%D6:+V=F;D)Q
M+J$%B.N4EX[(%C)`5%#]B9O?T&2H)N7==LM19M4#N2`8B4HT=(G$!*7U(EAC
MI$H??6\Z'2@SW@5DY9=DKHI;EL>BJP!#IGDF%+4A*G6T)=VD'=9JREYPBB+8
MQ@`JYV2W;O[0]D2REX&&",=X=/'DV;E3`BG'6MOQ!),$RBO+24Q)N1$H"("H
M9R[,)S?E.<1,/Q'I$"GR$\AFZ>4+S4NO#'B^LVWC'Q*R%_=T>4%^S&5&M;EO
M)LN@`DK_`)_6+TB49?/ZJ]FERP91BC(OEFY'3U591/VFQ$0E_EKQ;BWPF\'7
M.O,<>I.6\>Z#(\?[35(&)BRQE<4N-VGTDF40S?S4BM^W=`O]D<"8OOO7+Z5?
MJ"8QSG'U#TB-7]*_.0L7X2>,:DI+QD:FOI.Z0B"D@_:L4UYF4W*X-XV(0.Z5
M1*O)R+APFF@@03*K*'`I"B(]ND06GU(#MNV\W7@O.JH!00O>>*J@`&.<B:G)
MJFD3.)"@)A`YDS`'8/X!Z1#!_5`\?+WR'\/7(..SJ*=ST_D]CS_='D''H*.7
M\A5,\G3&NJS5ND4ZBQH.JRSN2.4H"8461^P"/PZ1/CZ7S<JWL_AHXR1,1)(.
MIW$7FBXQ=(XK@BSN&F(&\SEAAV[M,#"HB5_3[/&ND0$`#VE@`/U1[(AS=0U/
M.<4H=@T_6KG`Y]GM529+6&W69Z2/AHHLE),X:-(X<G`1,XDI>1;M6R1`,JNY
M7(FF4QS``HE(GZU+$+T>O\#^7M:CGTC4,OLE_P`PM;U%NLHTKLW;5ZG=Z&ZD
M_0F(M&TV>I2+<JB@E("R)$_UU"`*)=!XQ[14>1?'3#=WH4HUF*AK64T2^0C]
MFNFX2,WL-<8/EFBATS&`CV,>**-G"8]CHN$3D,`&*(=(FVWW6\YS"3S>%O=H
M:0$QKU_99=FL6HW?/7]NO;Z$G+*E!1K6.:NUBBA7JR_>N'"H)M6K9J=190A>
MW=$I7?6+HJIZQXB910@DCTM:U9!5X?L5!-8EHP-P9-0XCV(((`)OC\.P#^8>
MD2\L!@.'J+W,7T%/ZBAW`2B4!`P=N_<!`>D2C%]00('^H8\()2B`F"9P01*`
M@)@[\K7PE[E#XAZNWP_/TB7GEO@"X_\`16_K3=(E'/Z-H0&V>6`0,4P#LF6B
M`E,!@$!E=I[&`0$>Y1_@'\@](EB/SOO0C_#QY#EQ3,K[G&ZVLO240*(#).HR
M.!3N(#^BB+KUB'\(%[=(D.?I3E"'\)G&P"'*84[SR"34`H@/H/\`RUW,_H-V
M_(;TG`>WYAZ1"(<]/(SE_CYOG#E+<G4?7,@Y.;+8</LFC2*WL,\TL"],=V&C
M6:85,<J"%5<ST>$?)N%.Q&2#P'1Q!)!0>D3CYS\*"<GHR'T7-'\0TU&$B$VK
M0[IPF2#OU9/ZWK!@M*(BH@U>-3KF.Q=CZD3D5%,X@02G(B`EG.*_)*NRYX*5
MPS3`D"*BD4&-6D)ADN8#"4#M9.)3>QKE$XA^B<BHE$/X>D2?W#GQNW^5N,#H
MW("!&GTZNOFDS'422414LEKD62H+L4YEFW54+"02#E,JBQ%C?,N`+[?H*4PF
MZ1"UQO+#%YOE?.\,*_9$9O<J;C*>YWV`BQ1<MJ)39&S0U7K+6RN$E!"/L%H<
M2QG31B(`L#!#WS@1-9`5$2I[]5Y_A4X9_P"+S7?XS4WK6>?^NK\F_JGK%_#>
M_P!N>4_WW2_=7R+/TPP!_P#H=;/YMVA?QIH/4=Q'^:5_V6_HG1?X@G_"&O\`
MZ[K?N=F7_.MWGBQ.PZ1,101!01#X"';^D'2(#_D1X'N*6E[X/+WC/>-=\?O+
MHSAT\?;5Q/FXVLQ]K=R"HK29[_ETQ'R5%LZ$TKZ3222:#(LH(>IW[QOTND1W
M8GB9Y4$(G]VYKRZ0<C'E;)M0N$=X_<<C-/43*!DU5QDW&BRF?)R1T?3Z5OW:
M,F"G<PI"`@4$1JJAX!/'T[T":V[E/7-`Y_\`(2T$:%LFQ\R[FYTEZY39@H#6
M-AL^AV]7RNN5YB"HE:,&T*"+1+LFEZ2AVZ1"_9QF]!Q^BU;,<LIU=S[.Z1$M
MX&GTJHQ;6$K59A6HF%M%0D2R(FTCV#<3CZ$DR@0O?X``=(E?_EQ].KF>U\ZD
MO(OQ;Y9[-P7Y.OYLEHM=BS6O0%X@9NUGC`@Y:S,(2>D8<8A_:(@3(R[559[%
M2(J*&5:=U5O<1)F&\/F"Z?2;E$\UM+V7GII-ZSJV9H[U;D--P0GSV$NL*Z@[
M`\P7+Z7!5O)L6GUF[D%$Y>,ASS@*)E`[Y1/N042(_`WP!EX3N<]IS_GOONV<
M:L2U:7WC#N,\_2<_JE+J&UNV4@UK^BVR=BR2,[?'M->R:DHPC3&80I9LB;TS
M03@)3(FC<IOIOH3FANE(Y)<C/)5S:N^Q9B6%3S.TL(SC[3TL\2KD\I:(,M0A
MJED\/$1"["PJ?.>^5$7"K@`.HH<2E[(AK\>B`P*B&RWD'R[7Y"6Y4[V2/;]U
M#%:+<7=4D&Z,:WB']<H%?HE=D(9,[-Q_;2D<*KDZRI5%#@4`+CV[>I0W9?;6
MCD>C,`?YB9G:_&<EMU^]J:]]M/=CN2MV&?AD`C/7T]8'FI>)2H\<>0-YV'Q`
M^0."X82FXNRS&E\7GU;H?)7C5?92._:#H96M9@ZNM6M%*>,$WZQTU(J2.#)(
MPHH`@T$4.J:]W2M?VZKJFL/X!U)_F!S*K^)Y76J:_9U=BNE<99JW51GH,DJ`
M,GTS)K9[P;O&R7NG:#SGYFI<U'>'W6-ME*Q#/L[IV)\::+JU>$SF"N5RS6MV
M*\6G1K[45U2NH@+1/.F,4Z[.6[`C@J:Q+Z6U69%;*Q4X."#@_`X]#,6[6V-<
M*;ZW0.O<O<I7N7XKD#(_:.D(#NV$Y'R:R6\X5N]$@]*RC2(96"N-.L*!U6$H
MQ.JFX1536040>1TG'/44W+-XV42=,W21%D5"*$*8*Y9@2^//AXY@^/YK+YSX
M[O)O+4+C')3TI/0G';E-QSK_`"3B<W=3#Q1Z]+GUWC;]F%EC&2ZZYSJ,Q`&Z
MZHBLJ!W!U5CHA%L&X5VFIZO'\CN4?(BU<M>0]>K\U5,\L,K2ZWE638I7K.1J
MG;6^-8Y55I%C7Y^X(,TF\K/RLE,SKMDB1J5TBU%1%1$;'RP>*/"O+5Q_A\9U
MRP67.[50K.-WR'7::DV>S^?VA9H$=)^]#/E6[&QUN?C@*D^8G5;G4,BBJDNB
MLB10$1J^-'C1Y94\N:+\Q/)YL/+`^"L)#^06"@\KH^)5BL7$:U)52M:AJ1(=
MY99_?KI28N54/%)61ZM$$=?VPY:.G'98$2'?)+Z;N%Y<<A*1RJW[R7<WKCO.
M9%K!,VO4?'<?J@;/R4V>6M%:+4(6J9/$0D*,98W*CT#IH>XJY.)U3''I$+!:
M^(O(NT<<XW$!\CG).!NZ4[*NK!R-@*!QPC=9LU4DH]VP2I:S=+)OW'@48\S@
MJR4I&1;27]U,!^8#X]T06_`_Z?6A^,74EKGQF\CW*^C.]3F:\2^4&S-N/,Y7
M]K:TYV_L!:_)Q%BS)R^</",'D@!GL4="4:MG2YTUB`(CU2SHK!6(#-Z`GU_+
MXRZE%UB/96C-76`6(!(4$X!8CH`20`3CJ<0A'D=\<%B\C5(FL=LO,_D)A.!W
M"M1]?T#',<@L>3B+XI'S2DT#Z?MMMH%AOA&[I5-LFNP:R+=@L1J0#I&]:@'J
MEJ-IXR?$>KXNHIGG>2\VN2FE<?&;BSRR/'S4H7&'U*;62T^E5Y8(J?@\[B;Y
M"+$?E^:%HUDTV"S@QSJ(F,<XF1`9_6U?ZE_#?^<_8?\`-38.D2MWXNOJ=></
MCMJ<!BMWCXCEAQQKB2#"MT+29N0A[WG\0D=$"Q.?:BT:RD@S@VJ*8E;QLJSE
M6;8G9-L#8GPZ1++=>^MCX-NH,'-FXF<J(*P%1]1X6%?Y78HL5_;]0I-IQW;:
MXNHE[GZ('48I#V^/I#\G2(,[F_\`6?;EI%6FJ1P8X\QW'M689.&(['JD\PT?
M0XI-R!TSO*K3F,:TI$!+)$-W37?*S:9##W!$#`!ND3)^C7T*\ZQY#^=FE:9;
M;#?+_=^."5CMUQM<J[F[%8YR2V&H+O926E'RJSIXZ74-\3&-^B4`*'8H``(A
M$?JO/\*?#/\`Q>:[_&6F=:SS_P!=7Y-_5/6+^&]_MSRK^^Z7[J^18^F'_P!X
M=;/YMVA?QIH/4=Q/^:5_V6_HG1?X@G_"&O\`Z[K?N=F7_.MWGBQ.PZ1,-7_M
M#?T/ZT.D3CZ1%TB+I$72(ND1=(BZ1%TB13WS%<N/4.2&N/*/79/0[3@$]4I2
MS2T4PE)']W*15KW(5R)8K/6RRD>S:2%H>KF(D8I5550,8!$I>T/R6AJ-1L;=
ME:ML'7*Y(!P%5B`,CIU))^/3X3</'.=Y8;W&<,E]B<;5R*6!%8J.^VRH.QP1
MDD(HR?0#'XR'OBDQC,;-X[/&W?9.E5X;GG.)4:W5*T-(J/93L;-RE&FJG*J#
M*MVI'R[:4@I]PDY2,IZ%Q$AC]S$*(8'`\?IV\3H[35J-BM%<,``<E2IR<9((
M8Y^)P9N7W;YWEM3[C^3<=3?9^AV=ZVNRLL2A1;5L4=I.`59%*G'3J!ZF,)7]
MNN/$F^^7#:J=EE$G\PS3E7G-TTQ@I9'%4LTM$RN"8<UMBM*C(JMR$4M9(YJ^
M-(F4DED$I%<XI>HIQ,L6'JWMCB=GE=RFNMM2O95GR2&(*(#V@*1D9SDD9]/V
MS9-G@='S'C_#^#W=O8KY;:XBZJ@A!8BLNWM&OW69PP0D=F$!*`=W484SGV#F
M;;(':+M@6&Y*\UK1,VP>!WBTM5?VZ@S?)7:6L<5G6;Q*T#$RPQUFN(U"04-(
MOP3CH\A4?6"ONF]N;WN<NJW&T=&DW7I2+&Z,?J^E!V@X+?\`D?E'3U_#0.$\
M'T]C@Z/(>?W%T^-VN0?5K/R9'M*C77-WLO<E?N(.Q,N_S8Q@9ZG4N77(*!U[
M`<8S3CE6I*U\A^/^BZ_`L]3T]S1G^?VG-&E'?S]!T9G"5"V(M@`UV0CB/(Y=
M]VD>XF2!N0RO7W:Y;DTVJ-34UD+WT%_G?M*%0"58!3\0O0GJ?P`E[B?#?&]C
MAN1YOE.3M74XWD:==C10+1=7<;0EM):RLG_Y,Y5POR>A[B!,/DQS>OW&9*9G
MK;FM`-!UEKCSUS56NE+SFFW%C?K!"UJ^S-9@Z_77C:K5W-I><*V;R%A^2:3J
M[94J:C<#)">WR?.[/&,3;74$4(>WOR[=Q`8J%![50G&7P&(Z8Z2OQ;P/CO*>
MS7T]K8_46G9`L-`6BLTHSU*[.X-CWJG<4I[FJ#`D-@XW>Z<C-]3Y@S7%#.,P
MR>0(EQUC^0$'HMUT2TQB(MEKXXH#FLS=5@Z/)ND72TNW$R#AL[63*W_LB@>L
M`2-E[&_R0Y/_``[5KI(-/N!F=AT!"D$!3USZ8.,=?V3`T/&O'6\,3R[E-K<4
M_P")'4>FJFMCGVA:'6QK5!':>H90>[H.GS!FZUY,HZ\T;C=^[&6RZ.T\A-=V
MO$G.=.'#ZQQF;VWC2K9VVZR<A*5F,6E+;7Z^\K`)Q8LFJ"TD61;**`V(5;T8
M'_Z;W-6AJ:B=V^UZ^SJP0U__`$/RCN8#IC`!.1G'63>S]K+='D.3_5[:'@N-
MT];:%P`1KJ]WL.JH6Q@M;N'R_<Q"%&`[CVY<::YC:S4*3QXL]]X[NJ-,:WRM
M@>+UOJ]FLZT=(P:5IL<U`5;6Z04D([-8:C8V<062192014@B@Y*DJ!54C@-]
M^:W:M?6NNU_;-VT*65B01W'"NH[>JD#.&[2/21E'A/#[F_R6IQ_)#8IT^(?>
MK=$#*WMHKOKV_..RQ"W863W$)4D=")JNM\S-9@\C\E\C6:)28;0^#S&2_=5_
M)666F:U=63O%(+986PR#9&`9/HF390]A(BI'@"Z)WJ'87`(G]0-SE=ZK1Y"Q
M$K78U,]OS$@CL#AO3H<'Z?3/3..LRN&\)X?8YGQ>K:V+[.-YTK[@5%5ZR-E]
M9D!+D,I9"0_0]I^GN&)FWO3Y=AI/C82U_%,BOMJUK0K5"5S2$II^[L&,W%7C
MU>[LM;J0SE::W,HYM56KSR+?BFY8F0*\$A063Z^?J+S=Q_ZZFE[K"V'!)*'V
MRV1E1U8#!],?AGUE.CQ-+\9Y0>%WMS7U-/7K9Z2H";-?ZRJKV[2MAZ5V.KIE
M6SVY/:8X>=<H-1W*>N<QB655>RY-G'(^<XZ6F3LUX<5>\RBM"FF]:UG2:S%G
MA'L"->H\\LLDTC7+DLA-)L%SIB@)T"*9&OR>YNV.^E4C:=>P:B2V'/:<.X&,
M84^@)RV#Z=,QO)>*<1P.O11SNY;5S&UQB[E:I4+*E]U2^O0[=P?OM3!9U7LJ
M+J#W88C`Q;F>MKG)G3^.ZU>JE3G<OEKXSL-.L-CEH+98ROUJ4BXVD:,C1IV"
MCV-VS76FKT[YA,P#QZTC4_9;NC?,*F*G1I\S;M<G9H%$7VRX()(L`4CM;M(`
M9;/4%2>WIGUESG/!TX;Q74\D%MUU&TE)2Q$5]9GL5FMI]U')JNUR`KUW*K.>
MYD':.M9[ZVK_`%+^&_\`.?L/^:FP=;!.>3S;.D1=(BZ1+J/T2O\`KL<P_P":
MM&?YVZ=TB%"^J\_PI\,_\7FN_P`9:9UK//\`UU?DW]4]8OX;W^W/*O[[I?NK
MY%CZ8?\`WAUL_FW:%_&F@]1W$_YI7_9;^B=%_B"?\(:_^NZW[G9E_P`ZW>>+
M$[#I$Q5"F$YA`IA#X?$`$?X`Z1./T'^Z;\(_9TB+T'^Z;\(_9TB+T'^Z;\(_
M9TB+T'^Z;\(_9TB+T'^Z;\(_9TB+T'^Z;\(_9TB+T'^Z;\(_9TB+T'^Z;\(_
M9TB-SK.=*:OGELSH]LM-'9W*$DZY*S].)"!8D8::8N(R5;QJ]AAIV.9KNF+H
MY2K_`"QE43=C$$I@[]8N[K'<UFUA8]8<8)7MS@]"/F##J/QQD?A)/AN2'#\G
M3R?LU;#T6*ZI9W]G<I#*6",C$`@=.[!]#D1O>+G&Z!XH8E1,!I=OO%OH>9PC
M&L4<]^5@'L]#5B,3]J/A%).O0%<))H-2"(%5<)'<>GL43B``'5GC=#_#=5=1
M;;+*D&%[NW*CX?*JY'YY/[9(^5^2W^7<Y?Y!N444;^RY>WVN\*SMZOAWL*D_
MB`0/QQ(_V_QTT.[U'EM2IS8MQ&%YH6R*MVNBT>YZV>L743#PM;2CJ0Y#/C_N
M_%N:W6HUDJ50KI44V8'*H5514YXRWQRJZK:I>^[LVW#6?1^'3`^3H,`#\?3\
M\[)I_<OD-#<X?>U]'0]_@Z6KU\BX@AF9^ZT>]\[!W=ACM&6P00``[DKQ.A%]
M,A-KK.C:)1=@;Y5%XK<K[7$:8JZT_/H616FH1I=(.:J4I6_V]7IMZ[=1LE'M
M&3AF9^Y3+W04]HN8_$*;EVJKK:]L5"MG7LRZCJ.X%2N0>H(`(S\.DAJ?,+UX
MNS@]K5UMCA3MMLUU/[N*+F`5C4RV*_8ZA5='9E;L4_4,GL97BQ69?<,6WQQ>
M]0"V830;7F]2B59F&D*_+UV]$@"W%6XC*5Y[8)^:GE*K'*J//GTE4U6WJ3]/
MN*^NL\6GZRG=]VWOIK[`"005.,]Q(+$G`R<YR,RU5Y;MT\#O>/+K:GZ3?V$N
ML;M8.KU=_M^WVN$14]QP%[""&P<X&&7U7QQY3K=GY(V&9TG<X%GRG:9J;4:O
M5[9!,H/]OY$P9Q]!L-=</ZI)6")+#%CD5SQ7SJD*Y=%,HJT,*BH'PMOQS6V[
MK[7MO5=GM[U4K@E/I/52>G_CGM)]1)SB/N9R_#:G&:U&KH6/Q)O]BQZW+=FP
M2;D<"Q4;NR1[G:+0N`'&!AD);*]&DO)9'E@[=R2J<3!<!8[+S[\TS)25KMCO
M2>Q/;5(0L]=K1F,MD<C95*V[)()_+@BFW<B**0`H4S;K#LU[FYY*J[-I.S3*
M&T5DAF[@V"[5FLDCKTQ@C`Z])/4<MQM7VP=MBGC+KK/(3?\`I#?VNE7Z<5AD
MJKO78"=X[#G)*_,>F&DD6/C]Q*N9_A5,HKN[TBP<;[Q9-,RO5HR692>D-;_?
M`L/\J%CM4A/Q4G"W(VKC;)$;"U?,3M7AG(&331,B@*4D.!TTUZ*:2Z6:[ETL
M!!?N;/>3D$-WY/<",?#&!-8?[B\]L\CR&]R"T7ZW)ZZ47Z[*5I-579["5A&5
MJ_T_MI[+*X9>WJ6[FSOVG<5H76L[K5+MNCZ>O9*9K%4W*IZDD^KQKC7]0I4Q
M^V*]+Q\:ZKCFD$@60G4:!#FBC1XLU#$]OW!]SJ[?Q%>SK+1=;<UB7"T/D=P=
M3D$#M[0!Z!>W&/PSUD=Q7ENQP_)V[VGJZ@U;].S5LH[7]MZ+5[74L'%O>>C>
MY[G?W`'..DT"!X$YQ'1O+6&L>@:_?XKFK%%8[:TM<[`>I615SQMF,C/U!W"5
MB(=U=Z_JS)!(K9(YX]J*"?RZ"12^D;%?`TK7LU6W765[:XL#%?4KVEE(48)'
MX?2,#`DCL_<+D[;>'OUM;3U[N#?.J:T?Z1<;U2P/8PL`<D]Q`=LGN8DYG8S'
M"QA8GG%Z5G]SVZ5F>)]I7N-"E%E,X26L4VYITIG:IKLW;YZBSD&0T6<>QWLL
MTV)1^9.X$1<^E4OT\*2VLS;-Y;68E3\G7([<-\GIV_+@8^/KUE%/G-FNG*U:
M_'Z*4<O4*[5`OPBBQ;A[1-V0?=57RQ?Z0OTY$V2F\2:UF]RT6>SC0-*HU,UK
M2W&Q7[)X)[`$ITCI,H>/7M$]"RCBOKW:J-+P^BT7,TQCY1%H\7%8Q2)?,+^N
M[7Q%=-SOKVW5T66>XU:D!2WJ<'M[E#$`L`P!Z_$S$W?,=KD]'6U^3UM78WM/
M5&M3L.K^XM*Y"(RAQ58:@Q6IGK+*.WJ>U<<\#Q-J\9KU2V:<NV@WNRYVYUES
MG2=P7KSP::GM#\7EPAF4XPK\?9Y*K,T.S:)BWKUPTCD"E]!3'31,FIX>JO;3
M<>RRRRLV%.[M^7W#E@"%#%1U"J20/YL?-GS#;NX:[A-?7UM?6V5UQ=[8<>Y^
MF&*V*EV06$_-8ZJK.<Y(!8&/GDP\5/&KRMYSG&7<FY+4XNM9==GM^KA\MLL3
M6)):<?P+JNK$E',S6K,@Y8E8.SB4A$DS@IV'U]NX#+S48&K_`(-KQ-_W5\P/
M\K-'_P!$W2(O^#:\3?\`=7S`_P`K-'_T3=(B_P"#:\3?]U?,#_*S1_\`1-TB
M$F\:'@JX8^*73-#U?C),[C)V;3*&CG=B1U*Z0%GB4X%"P1UE(K'-(:F5E5O(
M_M"+2#W#J*E]KU%`H"/?I$>WGIXI^-7D6GLYL6^R>J1[_+XBP0E;+GEFBJ^W
M49V1]'2$@:33DZW/&<KE7C$P3,04@*7N`@/<!"+Y#BZ^096L>Q.S/TD#.?CT
MG>_LW_V,\^^QNGO:/AE?'O3R%M=EOZFJRPAJE95["EM>!ASG.>N,8FB\(_#)
MQ,X";`^VW#Y?9']PD*9,45PA?+=#3L)^Q9M]$R#PY&,=5(18'Q5X9'VU!5$I
M2B8/2/?N%G2X2C2V1LK9:S`$88@CK_)F3/W:_P"U'W*^\WBZ>)>6U<6G%IM)
GL`Z]-B6=]:NJCN>ZP=N+&R.WKTZ](67T'^Z;\(_9U-3\US.Z1/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
